• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Henry Ford Hospital first in U.S. to start trial in aggressive brain tumors

Henry Ford Hospital first in U.S. to start trial in aggressive brain tumors

February 6, 2012
CenterWatch Staff

Henry Ford Hospital's Hermelin Brain Tumor Center is the first U.S. hospital to start a new clinical trial for Toca 511 & Toca FC, a combination therapy under investigation for high-grade glioma (HGG), a fast growing, brain cancer that often recurs even after surgery, radiation treatment and chemotherapy.

The investigational treatment combines Toca 511 (vocimagene amiretrorepvec), a biologic drug, with Toca FC, an extended-release tablet containing the antibiotic flucytosine.

"The combination of Toca 511 and  flucytosine has been shown in mouse studies to destroy brain cancer tumors, leave healthy tissue unharmed, and extend survival in most animals," said Steven Kalkanis, M.D., co-director of the Hermelin Brain Tumor Center.

Glioma is very difficult to treat successfully because, rather than being a clearly defined mass, the tumor blends with healthy brain tissue and sends out tentacles of microscopic cancer cells.

Standard treatment begins with surgery to remove as much of the tumor as possible, followed by irradiating the brain and chemotherapy in an attempt to kill any remaining cancer cells. Even after these extreme measures, the cancerous tumor often returns.

"The focus of the clinical trial now being conducted at Henry Ford and other leading U.S. neuro-oncology centers takes a radically different approach to killing the virulent brain cancer," said Tom Mikkelsen, M.D., co-director of the Hermelin Brain Tumor Center.

In this clinical trial, immediately after surgeons remove as much of the recurrent high-grade glioma as possible, the biologic drug Toca 511 will be injected into the "bed," or portion of the brain from which the tumor was removed. Henry Ford Hospital is also participating in a similar clinical trial whereby Toca 511 is administered at the time of tumor biopsy.

After allowing time for Toca 511 to spread through the tumor, each patient begins a course of oral Toca FC tablets. If tolerated well, these courses will be repeated. An MRI scan will be performed every two months during the trial period to measure the treatment's effectiveness.

According to Tocagen, the San Diego-based biotechnology company that developed the investigational treatment, Toca 511 is designed to selectively deliver to cancer cells the genetic instructions to produce the cytosine deaminase (CD) enzyme, which can then convert the antibiotic flucytosine into the potent anti-cancer drug 5-FU inside the cancer cells.

Henry Ford is now screening patients for using this investigational therapy. To be eligible for the clinical trial, patients must be at least 18 years old and be considering surgery to remove a tumor that has recurred or progressed following surgery, radiation and chemotherapy with temozolomoide.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing